Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma

Authors: Akihiko Takeuchi, Norio Yamamoto, Toshiharu Shirai, Katsuhiro Hayashi, Shinji Miwa, Seiichi Munesue, Yasuhiko Yamamoto, Hiroyuki Tsuchiya

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcription factor that belongs to the nuclear hormone receptor superfamily. PPARγ is essential in adipocyte differentiation from precursor cells. Its antitumorigenic effects are reported in certain malignancies; however, its effects in liposarcoma are unclear.

Methods

We analyzed PPARγ expression using immunohistochemistry (IHC) in 46 patients with myxoid liposarcoma [MLS; median age, 47 years (range, 14–90 years) and mean follow-up period, 91 months (range, 13–358 months)]. PPARγ mRNA expression levels were measured by quantitative reverse transcription polymerase chain reaction. Further, we evaluated the correlation of PPARγ expression with clinical outcomes.

Results

We found that the metastasis-free survival rate was significantly higher in lower PPARγ expressers [34 patients with labeling index (LI) <50 %] than in higher expressers (12 patients with LI ≥50 %; p = 0.01). Cox multivariate analysis revealed that a higher PPARγ level was an independent predictor of metastasis (relative risk = 6.945, p = 0.026). Furthermore, using 28 fresh MLS specimens, we confirmed an increased PPARγ mRNA expression level in the higher LI group (p = 0.001).

Conclusions

In this study, higher PPARγ expression in MLS was a risk factor associated with distant metastasis; therefore, it would be a novel prognostic marker for MLS. Further analyses will help to understand the correlation between PPARγ expression and tumor malignancy in liposarcoma.
Literature
1.
Goldblum JR, Folpe AL, Weiss SW. Liposarcoma. In: Goldblum JR, Folpe AL, Weiss SW, editors. Enzinger & Weiss’s soft tissue tumors. 6th ed. Philadelphia: Elsevier; 2013. p. 484–523.
2.
Antonescu CR, Ladanyi M. Myxoid liposarcoma. In: Fletcher CD, Hogendoorn P, Mertens F, Bridge J, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013. p. 39–41.
3.
Smith TA, Easley KA, Goldblum JR. Myxoid/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma. Am J Surg Pathol. 1996;20:171–80.CrossRefPubMed
4.
Grozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993;363:640–4.CrossRef
5.
Rabbitts TH, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet. 1993;4:175–80.CrossRefPubMed
6.
Demicco EG, Torres KE, Ghadimi MP, Colombo C, Bolshakov S, Hoffman A, et al. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol. 2012;25:212–21.CrossRefPubMed
7.
Pitson G, Robinson P, Wilke D, Kandel RA, White L, Griffin AM, et al. Radiation response: an additional unique signature of myxoid liposarcoma. Int J Radiat Oncol Biol Phys. 2005;60:522–6.CrossRef
8.
Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005;41:2853–60.CrossRefPubMed
9.
Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 2002;16:22–6.CrossRefPubMedPubMedCentral
10.
Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1998;1:465–70.CrossRefPubMed
11.
Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell. 1999;3:799–804.CrossRefPubMed
12.
Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A. 2000;97:10990–5.CrossRefPubMedPubMedCentral
13.
Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000;289:1357–60.CrossRefPubMed
14.
Takeuchi A, Yamamoto N, Nishida H, Kimura H, Ikeda H, Tsuchiya H. Complete necrosis of a giant cell tumor with high expression of PPARγ: a case report. Anticancer Res. 2013;33:2169–74.PubMed
15.
Tajima T, Morii T, Kikuchi F, Matsumine A, Murata H, Nobuto H, et al. Significance of LRP and PPAR-gamma expression in lipomatous soft tissue tumors. Open Orthop J. 2010;4:48–55.CrossRefPubMedPubMedCentral
16.
Green FL, Page DL, Fleming ID, Fritz AG, Balch CM, et al. Soft tissue sarcoma. In: AJCC (American Joint Committee on Cancer) cancer staging manual. 6th ed. New York: Springer; 2002. p. 193–200.CrossRef
17.
Scotlandi K, Serra M, Manara MC, Maurici D, Benini S, Nini G, et al. Clinical relevance of Ki-67 expression in bone tumors. Cancer. 1995;75:806–14.CrossRefPubMed
18.
Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A. 1997;94:237–41.CrossRefPubMedPubMedCentral
19.
Nishida Y, Tsukushi S, Nakashima H, Ishiguro N. Clinicopathologic prognostic factors of pure myxoid liposarcoma of the extremities and trunk wall. Clin Orthop Relat Res. 2010;468:3041–6.CrossRefPubMedPubMedCentral
20.
ten Heuvel SE, Hoekstra HJ, van Ginkel RJ, Bastiaannet E, Suurmeijer AJ. Clinicopathologic prognostic factors in myxoid liposarcoma: a retrospective study of 49 patients with long-term follow-up. Ann Surg Oncol. 2007;14:222–9.CrossRefPubMed
21.
Kilpatrick SE, Doyon J, Choong PF, Sim FH, Nascimento AG. The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer. 1996;77:1450–8.CrossRefPubMed
22.
Cheng EY, Springfield DS, Mankin HJ. Frequent incidence of extrapulmonary sites of initial metastasis in patients with liposarcoma. Cancer. 1995;75:1120–7.CrossRefPubMed
23.
Asano N, Susa M, Hosaka S, Nakayama R, Kobayashi E, Takeuchi K, et al. Metastatic patterns of myxoid/round cell liposarcoma: a review of a 25-year experience. Sarcoma. 2012;2012:345161.CrossRefPubMedPubMedCentral
24.
Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002;110:923–32.CrossRefPubMedPubMedCentral
25.
Elstner E, Müller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A. 1998;95:8806–11.CrossRefPubMedPubMedCentral
26.
Kristiansen G, Jacob J, Buckendahl AC, Grützmann R, Alldinger I, Sipos B, et al. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res. 2006;12:6444–51.CrossRefPubMed
27.
Forootan FS, Forootan SS, Malki MI, Chen D, Li G, Lin K, et al. The expression of C-FABP and PPARγ and their prognostic significance in prostate cancer. Int J Oncol. 2014;44:265–75.PubMed
28.
Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, et al. Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer. 2005;92:113–9.CrossRefPubMed
29.
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953–6.CrossRefPubMed
30.
Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer. 2003;89:1409–12.CrossRefPubMedPubMedCentral
31.
Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer. 2012;118:5403–13.CrossRefPubMedPubMedCentral
32.
Pérez-Losada J, Pintado B, Gutiérrez-Adán A, Flores T, Bañares-González B, del Campo JC, et al. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene. 2000;19:2413–22.CrossRefPubMed
33.
Gronchi A, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol. 2012;23:771–6.CrossRefPubMed
34.
Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009;8:449–57.CrossRefPubMed
35.
Guo S, Lopez-Marquez H, Fan KC, Choy E, Cote G, Harmon D, et al. Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma. PLoS One. 2014;9:e93996.CrossRefPubMedPubMedCentral
Metadata
Title
Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma
Authors
Akihiko Takeuchi
Norio Yamamoto
Toshiharu Shirai
Katsuhiro Hayashi
Shinji Miwa
Seiichi Munesue
Yasuhiko Yamamoto
Hiroyuki Tsuchiya
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2524-6

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

A consultation training program for physicians for communication about complementary medicine with breast cancer patients: a prospective, multi-center, cluster-randomized, mixed-method pilot study

Research article

Melanoma-specific mortality and competing mortality in patients with non-metastatic malignant melanoma: a population-based analysis

Research article

Cervical and breast cancer screening uptake among women with serious mental illness: a data linkage study

Case report

Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma

Research article

Increased Wnt5a in squamous cell lung carcinoma inhibits endothelial cell motility

Research article

Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits